Oleanolic Acid

Oleanolic acid (OA), a pentacyclic triterpenoid with the molecular formula C₃₀H₄₈O₃ (MW 456.70 g/mol), exerts antimicrobial, antioxidant, anticancer, and anti-inflammatory effects through membrane disruption, free-radical scavenging, and modulation of inflammatory signaling cascades. In vitro, OA demonstrates an IC₅₀ of 40 µg/mL against HCT-116 human colon cancer cells at 48 hours, while its synthetic derivative CDDO exhibits activity more than 200,000-fold greater, underscoring the scaffold's exceptional pharmacological potential.

Origin & History

Oleanolic acid (OA), the principal bioactive representative of the oleanane-type pentacyclic triterpenoid scaffold, is biosynthesized widely across the plant kingdom, with particularly high concentrations in olive (Olea europaea) leaves (up to 27.16 mg/g wet weight), aromatic herbs such as rosemary (Rosmarinus officinalis), sage (Salvia officinalis), and basil (Ocimum tenuiflorum), and the roots of licorice species (Glycyrrhiza spp.). The compound occurs as a free acid or as the aglycone component of oleanane-type saponins in these plants, distributed across temperate and subtropical growing regions of the Mediterranean basin, East Asia, and South Asia. Biotechnological production via engineered Saccharomyces cerevisiae fermentation has achieved yields of 606.9 ± 9.1 mg/L within 144 hours, providing a plant-biomass-independent supply route for research and industrial applications.

Historical & Cultural Context

Oleanolic acid-rich plants have extensive histories of use across multiple traditional medicine systems predating the compound's chemical characterization. In Traditional Chinese Medicine, species such as Meconopsis henrici and Dracocephalum tanguticum, both OA-containing plants, have been employed for centuries to address inflammatory, respiratory, and digestive conditions. The olive (Olea europaea), among the highest OA-yielding plants known, has been central to Mediterranean ethnomedicine for over 3,000 years, with its leaves historically used as antimicrobial and fever-reducing preparations in ancient Greek and Egyptian practice. Licorice root (Glycyrrhiza spp.), a source of the OA-derived compound glycyrrhetinic acid, has been documented in Chinese, Ayurvedic, and Western herbal traditions as an adaptogen, anti-inflammatory, and demulcent, appearing in texts including the Shen Nong Ben Cao Jing (circa 200 CE) and the Ebers Papyrus (circa 1550 BCE).

Health Benefits

- **Antimicrobial Activity**: OA and its epimer 3-epi-oleanolic acid damage bacterial cell membranes, exhibiting minimum inhibitory concentrations (MICs) of 0.9–7.8 µg/mL against pathogens such as Listeria monocytogenes and Enterococcus faecalis, potency comparable to the reference antibiotic kanamycin in controlled assays.
- **Antioxidant Protection**: OA neutralizes DPPH free radicals at 64.3% efficiency at concentrations above 1.0 mg/mL (IC₅₀ 1.21 mmol), with a stoichiometric ratio of approximately 1:1 (OA/DPPH), indicating direct radical scavenging rather than purely indirect enzyme induction.
- **Anticancer Potential**: OA reduces viability of HCT-116 colon cancer cells with an IC₅₀ of 40 µg/mL at 48 hours and shows cytotoxicity in lung cancer cell lines (IC₅₀ 4.7 µmol), approaching the potency of 5-fluorouracil (IC₅₀ 3.5 µmol) in comparative in vitro models.
- **Anti-Inflammatory Effects**: As a pentacyclic triterpenoid, OA is understood to modulate pro-inflammatory pathways including NF-κB signaling, consistent with class-level evidence across related triterpenoids, though pathway-specific mechanistic data for OA itself requires further direct experimental confirmation.
- **Hypolipidemic Properties**: OA and closely related oleanane triterpenoids have demonstrated lipid-lowering activity in experimental models, attributed in part to modulation of hepatic lipid metabolism and bile acid pathways, positioning the compound as a candidate for metabolic syndrome research.
- **Antiviral Activity**: The oleanane triterpenoid scaffold, including OA, exhibits documented antiviral properties across multiple viral families in preclinical models, with structure-activity relationship studies indicating the C-28 carboxyl and C-3 hydroxyl groups as critical pharmacophoric elements.
- **Scaffold for Drug Derivatization**: The oleanane skeleton serves as the structural basis for highly potent synthetic derivatives such as CDDO (2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid), which is over 200,000 times more pharmacologically active than the parent OA, driving active pharmaceutical development pipelines for chronic and oncological diseases.

How It Works

Oleanolic acid exerts its antioxidant effects through direct hydrogen atom transfer to DPPH and similar reactive oxygen species, with a stoichiometric 1:1 OA/DPPH quenching ratio confirming a radical chain-termination mechanism rather than purely catalytic enzyme activation. Antimicrobial activity is mediated by physical disruption of bacterial cell membranes, altering membrane fluidity and permeability, resulting in leakage of intracellular contents and cell death at MIC values of 0.9–7.8 µg/mL for select oleanane derivatives. Anticancer activity proceeds through concentration-dependent reduction of cancer cell viability, likely involving induction of apoptotic cascades and cell cycle arrest, as observed in HCT-116 colon cancer (IC₅₀ 40 µg/mL) and lung cancer (IC₅₀ 4.7 µmol) cell lines. Synthetic oleanane derivatives such as CDDO achieve vastly amplified potency—exceeding OA by more than 200,000-fold—through strategic electrophilic modifications at positions C-2 and C-3 that enhance covalent interaction with Keap1, thereby activating the Nrf2/ARE cytoprotective pathway and inhibiting IKKβ within the NF-κB inflammatory cascade.

Scientific Research

The evidence base for oleanolic acid is currently composed primarily of in vitro cell-line studies and preclinical animal experiments, with no published randomized controlled trials in humans identified in the available literature reporting quantified clinical endpoints such as p-values or effect sizes. In vitro studies have rigorously quantified anticancer IC₅₀ values (40 µg/mL in HCT-116 colon cancer cells; 4.7 µmol in lung cancer models) and antimicrobial MIC ranges (0.9–7.8 µg/mL), and biotransformation research has established reproducible microbial production yields of 606.9 ± 9.1 mg/L in engineered yeast systems. The synthetic derivative CDDO has progressed further along the translational pipeline, with bardoxolone methyl (a CDDO derivative) reaching Phase II/III clinical trials for chronic kidney disease and pulmonary arterial hypertension, providing indirect but substantive evidence of oleanane scaffold clinical relevance. The overall evidence quality for native oleanolic acid in human supplementation contexts remains preliminary, and well-designed clinical trials examining bioavailability, effective dosing, and therapeutic outcomes are an acknowledged gap in the field.

Clinical Summary

No completed human randomized controlled trials evaluating oleanolic acid as an isolated supplement have been identified in the current literature, and direct clinical outcome data with effect sizes or confidence intervals for OA itself are absent. The closest clinical translation derives from bardoxolone methyl, a second-generation synthetic oleanane derivative, which demonstrated significant improvements in estimated glomerular filtration rate (eGFR) in Phase II trials for chronic kidney disease, though Phase III results were complicated by fluid retention adverse events, illustrating both the promise and risk profile of the oleanane scaffold in human medicine. In vitro benchmarking of OA against 5-fluorouracil in lung cancer models (IC₅₀ 4.7 µmol vs. 3.5 µmol) provides proof-of-concept for anticancer relevance but cannot substitute for clinical efficacy data. Confidence in therapeutic outcomes for human supplementation with oleanolic acid remains low pending adequately powered translational studies.

Nutritional Profile

Oleanolic acid is a lipophilic pentacyclic triterpenoid (C₃₀H₄₈O₃, MW 456.70 g/mol) and is not a macronutrient or essential micronutrient; it does not contribute caloric value, vitamins, or minerals in meaningful quantities when consumed via food sources. In olive leaves, OA concentrations reach up to 25.09 ± 0.72 mg/g dry weight, representing its highest known natural food-source density. OA co-occurs in aromatic herbs alongside its isomer ursolic acid (up to 26.2 mg/g in some species) and other triterpenoids, flavonoids, and phenolic acids, which may act synergistically in whole-plant extracts. Bioavailability of native OA from oral sources is considered low due to its highly lipophilic character (logP estimated >5), poor aqueous solubility, and limited intestinal absorption; first-pass hepatic metabolism further reduces systemic exposure, motivating ongoing research into esterified and nanoparticulate delivery systems.

Preparation & Dosage

- **Standardized Extract (Olive Leaf)**: Olive leaf extracts standardized to oleanolic acid content (typically 5–20% OA by HPLC) are the most commercially accessible OA-containing supplement form; standardization percentages vary widely by manufacturer.
- **Isolated Oleanolic Acid Powder**: Research-grade OA is isolated via column chromatography yielding 15–23 mg per extraction batch from plant biomass; no established human supplemental dose exists in clinical guidelines.
- **Experimental In Vitro Concentrations**: Active concentrations used in cell-based assays range from 4.7 µmol (lung cancer) to 40 µg/mL (colon cancer) and 0.9–7.8 µg/mL (antimicrobial MICs); these in vitro values cannot be directly extrapolated to oral human dosing without pharmacokinetic data.
- **Biotechnological/Fermentation-Derived OA**: Engineered Saccharomyces cerevisiae produces 606.9 ± 9.1 mg/L OA in 144-hour fermentation runs; this form is not yet commercially available as a consumer supplement.
- **Enhanced Bioavailability Derivatives**: 1,3-Cyclopropane esters of OA have been formulated to improve oral bioavailability and achieve sustained-release kinetics in experimental settings; no commercial formulation is approved.
- **Traditional Herbal Preparations**: Olive leaf tea and decoctions, licorice root extracts, and dried aromatic herb powders (rosemary, sage, oregano) provide OA alongside complex phytochemical matrices; OA content per serving depends on plant source and preparation method.
- **Timing and Frequency**: No evidence-based dosing frequency or timing guidance exists for isolated OA supplementation in humans; traditional herbal preparations are typically consumed 1–3 times daily with meals.

Synergy & Pairings

Oleanolic acid is frequently co-extracted alongside its structural isomer ursolic acid in aromatic herbs such as rosemary and sage, and the two triterpenoids are hypothesized to exhibit additive or synergistic antimicrobial and antioxidant effects due to their complementary membrane-disruption and free-radical scavenging mechanisms acting simultaneously on shared biological targets. OA in olive leaf extract co-occurs with oleuropein and hydroxytyrosol, both potent phenolic antioxidants; this phytochemical matrix may enhance overall antioxidant and anti-inflammatory bioactivity relative to isolated OA, as the phenolics address aqueous-phase radical species while the lipophilic OA acts in membrane compartments. In experimental oncology contexts, oleanane derivatives including CDDO have been studied in combination with standard cytotoxic agents (e.g., paclitaxel, bortezomib), with mechanistic rationale based on complementary apoptotic pathway activation and Nrf2-mediated sensitization of cancer cells to oxidative stress.

Safety & Interactions

The safety profile of isolated oleanolic acid in humans has not been formally established through clinical trials, and no regulatory agency has issued an approved tolerable upper intake level or maximum daily dose for OA as a standalone supplement. In vitro antimicrobial studies indicate OA is selectively active against pathogens at MIC values of 0.9–7.8 µg/mL, suggesting a potentially favorable therapeutic index, but systemic toxicology data in humans is absent from the published record. The pharmacological trajectory of the synthetic derivative bardoxolone methyl in Phase III clinical trials revealed dose-dependent adverse events including fluid retention, heart failure exacerbations, and elevated liver enzymes, signaling that potent oleanane derivatives carry meaningful safety concerns that may inform caution around high-dose native OA use; however, direct extrapolation is not scientifically appropriate without OA-specific data. Pregnancy and lactation safety is unknown; no drug interaction data are available for OA with specific pharmaceutical drug classes, though its metabolic processing via cytochrome P450 enzymes is hypothesized based on triterpenoid class pharmacokinetics, and theoretical interactions with hepatically metabolized drugs warrant precaution.